Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

In patients with high PD-L1 expression identified before surgery, clinicians should consider the possibility of lymph node metastasis when determining surgical strategy, including the extent of lymph ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

Company closed $22M financing to support randomized Phase 2b trial; IND cleared and study initiated; Interim results anticipated in late 2026; topline data expected in H2/2027 ...

Jazz Pharmaceuticals (NASDAQ:JAZZ) used an investor call following the ASCO Gastrointestinal Cancer Symposium to highlight ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, al ...

China NMPA grants breakthrough therapy designation to Kelun-Biotech’s sacituzumab tirumotecan in combo with immunotherapy pembrolizumab for first-line treatment of PD-L1-positive NSCLC ...

Liv Hospital, the pioneer provider of personalized care, relies on the principle that each patient's cancer is different. The team undertakes to target the specific causes of a person's cancer rather ...

Breakthrough Therapy Designation granted to zoldonrasib for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic ...

Newly diagnosed patients with KRAS G12C-mutant advanced or metastatic nonsquamous NSCLC will be enrolled in the trial.

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...